Quick Dispatch:
Your surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide for Obesity Treatment and Diabetes Prevention orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide for Obesity Treatment and Diabetes Prevention ships.
Need Help?
Questions about surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide for Obesity Treatment and Diabetes Prevention, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide for Obesity Treatment and Diabetes Prevention in your area.
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
23.64
Adults with obesity using tirzepatide maintain 'remarkable' weight loss at 88 weeks
20.60
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
25.10
How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast
21.72
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
22.07
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
27.22
SURMOUNT-1 Trial
29.77
